Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 210

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination

Open access
Pozzetto, Bruno, Legros, Vincent, Djebali, Sophia, Barateau, Véronique, Guibert, Nicolas, Villard, Marine, Peyrot, Loïc, Allatif, Omran, Fassier, Jean-Baptiste, Massardier-Pilonchéry, Amélie, Brengel-Pesce, Karen, Yaugel-Novoa, Melyssa, Denolly, Solène, Boson, Bertrand, Bourlet, Thomas, Bal, Antonin, Valette, Martine, Andrieu, Thibault, Lina, Bruno, Covid-Ser study group, Saker, Kahina, Compagnon, Christelle, Mokdad, Bouchra, d’Aubarede, Constance, Pitiot, Virginie, Escuret, Vanessa, Morfin, Florence, Trabaud, Mary-Anne, Prieux, Margaux, Dubois, Valérie, Josset, Laurence, Daniel, Soizic, Cosset, François-Loïc, Paul, Stéphane, Defrance, Thierry, Marvel, Jacqueline, Walzer, Thierry, Trouillet-Assant, Sophie · 2021 · Nature

Abstract

Abstract Following severe adverse reactions in patients vaccinated with the AstraZeneca ChadOx1 (Chad) vaccine, European health authorities have recommended that patients under the age of 55 who received one dose of Chad vaccine receive a second dose of Pfizer BNT162b2 (BNT) vaccine as a booster. However, the effectiveness and the immunogenicity of this vaccination regimen have not been formally tested. Here, we show that the heterologous Chad/BNT combination confers better protection against SARS-CoV-2 infection than the homologous BNT/BNT combination in a population of health care workers. To understand the underlying mechanism, we monitored in a longitudinal way the anti-spike immunity conferred by each vaccinal combination. Both combinations induced strong anti-spike antibody responses after boost in all vaccinated individuals. However, sera from heterologous vaccinated individuals displayed a stronger neutralizing activity, regardless of the SARS-CoV-2 variant analyzed, and this was associated with more switched memory RBD-specific B cells with an activated phenotype and less IgA. The Chad vaccine induced a stronger T cell response than the BNT vaccine after the priming dose, and the reciprocal was true for the IgG response, which could explain the complementarity of both vaccines when used in an heterologous setting. This strongly protective vaccination regimen could be therefore particularly suitable for immunocompromised individuals.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-021-04120-y

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 210

Metadata

Authors
Pozzetto, B., Legros, V., Djebali, S., Barateau, V., Guibert, N., Villard, M., Peyrot, L., Allatif, O., Fassier, J.-B., Massardier-Pilonchéry, A., Brengel-Pesce, K., Yaugel-Novoa, M., Denolly, S., Boson, B., Bourlet, T., Bal, A., Valette, M., Andrieu, T., Lina, B., Covid-Ser study group, Saker, K., Compagnon, C., Mokdad, B., d’Aubarede, C., Pitiot, V., Escuret, V., Morfin, F., Trabaud, M.-A., Prieux, M., Dubois, V., Josset, L., Daniel, S., Cosset, F.-L., Paul, S., Defrance, T., Marvel, J., Walzer, T., & Trouillet-Assant, S.
Venue
Nature
Published
2021-10-21
Volume
600
Issue
7890
Pages
701-706
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W3189962012
Cited by
210
References
11
FWCI
13.77
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination. https://app.cochat.ai/papers/10.1038/s41586-021-04120-y
The paper
Pozzetto, B., Legros, V., Djebali, S., Barateau, V., Guibert, N., Villard, M., Peyrot, L., Allatif, O., Fassier, J.-B., Massardier-Pilonchéry, A., Brengel-Pesce, K., Yaugel-Novoa, M., Denolly, S., Boson, B., Bourlet, T., Bal, A., Valette, M., Andrieu, T., Lina, B., . . . Trouillet-Assant, S. (2021). Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination. Nature. https://doi.org/10.1038/s41586-021-04120-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.